Comments on: Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab in Combination with Axitinib for the First-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma

Comments on: Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab in Combination with Axitinib for the First-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma //zgzctx.com/en/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e8%82%be%e7%bb%86%e8%83%9e%e7%99%8c%e4%b8%80%e7%ba%bf%e6%b2%bb%e7%96%97-2/ 创新疗法的发现、开发和商业化的生物制药公司�?/description> Thu, 13 Jul 2023 09:21:11 +0000 hourly 1 //wordpress.org/?v=6.7.3